Understanding Nature’s Universal
OUR OMEGA EPIGENOMIC PROGRAMMING PLATFORM: EPIZIPS // OMEGA EPIGENOMIC CONTROLLERS // NOVEL DRUG DELIVERY // INDUSTRY-LEADING EXPERTISE
Omega Therapeutics was founded to understand epigenetic regulation in order to systematically control the fundamental biology of gene expression.
We have identified nature’s universal operating system for gene control and have created a new drug development platform to specifically target Insulated Genomic Domains (IGDs).
By co-opting this operating system, we have identified and classified roughly 15,000 IGDs in our genome, created a system of genomic “zip codes” to use IGDs as drug targets, which we call EpiZips™, and have developed Omega Epigenomic Controllers (OECs), a new class of medicine.
Through our OMEGA platform, we have achieved in vivo proof of concept of our OECs in in multiple disease models for various indications that modern gene-based therapies have not been able to address.
OUR BROAD AND TRANSFORMATIVE PLATFORM ALLOWS US TO ADDRESS CONDITIONS INITIALLY SPANNING:
Recapitulation of developmental and mature-state gene expression to drive cellular regeneration and restore normal function.
Multigenic diseases including immunology.
Regulation of multiple genes within an IGD or across IGDs.
Control of target oncogenes including historically challenging or un-druggable targets in various cancers.
Select monogenic diseases.
Correction of dysregulation in monogenic rare and non-rare diseases.
IGDs AS DRUG TARGETS
IGDs present differently in pristine and diseased states, and we leverage this knowledge to create therapeutic interventions.
Omega Epigenomic Controllers™ can target any aspect of dysregulated IGDs with exquisite specificity
and precisely tune the level of gene expression needed to restore native structure and correct function. In the context of single or complex multigenic diseases, we have proactively engineered nature’s own toolkit to restore healthy biological function.
TUNING GENES BY TARGETING EPIGENOMIC “ZIP CODES”, EPIZIPS, WITHIN IGDs FOR PRECISION GENOMIC CONTROL™
IGDs are nature’s system of organizing genes and controlling their expression, and we have characterized them by their genomic “zip codes”, disease correlations, and mechanisms of action. We call these epigenomic targets EpiZips. By precisely tuning IGDs, our Omega Epigenomic Controllers
regulate single- or multi-gene expression to desired levels to treat or cure serious disease with high specificity, tunability and durability, all without altering the body’s native nucleic acid sequences.
Through computational techniques including our diverse library of proprietary algorithms and deep-learning techniques, we have identified thousands of potential intervention points to target specific DNA binding domains, IGDs, and their sub-elements and regulators, because we understand their genomic addresses.
Our epigenomic controllers are able to tune gene expression individually or collectively, up or down, whereas gene editing or gene therapy have a binary and generally permanent effect, causing genes to remain all the way “on” or “off.”
We have achieved controllable durability of effect through our use of nature's own epigenetic mechanisms. We can tailor the therapeutic response of our Omega Epigenomic Controllers to last for a few days, a few weeks, or even a few months.
ENGINEERED AND MODULAR, PROGRAMMABLE MRNA-ENCODED THERAPEUTICS DELIVERED BY LNPs TO SPECIFIC TISSUES AND CELLS
Publications and Research Bibliography
Modulation of the MYC Oncogene Using Programmable mRNA Therapeutics as a Novel Therapy for Hepatocellular Carcinoma. William Senapedis, Kayleigh Gallagher, Elmer Figueroa, Jeremiah Farelli, Robert Lyng, Charles O’Donnell, Joseph Newman, Thomas McCauley.
Novel Epigenetic Targeting of the MYC Oncogene for the Treatment of NSCLC Using Programmable mRNA Therapeutics. Defne Yarar, Eugine Lee, Houda Belaghzal, Kai-Yuan Chen, Cameron Vergato, Stephen Siecinski, Jeremiah Farelli, Charles O’Donnell, Joseph Newman, Thomas McCauley.
Epigenetic Modulation of the MYC Oncogene as a Potential Novel Therapy for HCC. William Senapedis, Elmer Figueroa, Kayleigh Gallagher, Jeremiah Farelli, Robert Lyng, Charles O’Donnell, Joseph Newman, Thomas McCauley.
Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control. Hnisz D, Day DS, Young RA. Cell. 2016 Nov 17;167(5):1188-1200. doi: 10.1016/j.cell.2016.10.024. Review.
CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription. Tang Z, Luo OJ, Li X, Zheng M, Zhu JJ, Szalaj P, Trzaskoma P, Magalska A, Wlodarczyk J, Ruszczycki B, Michalski P, Piecuch E, Wang P, Wang D, Tian SZ, Penrad-Mobayed M, Sachs LM, Ruan X, Wei CL, Liu ET, Wilczynski GM, Plewczynski D, Li G, Ruan Y. Cell. 2015 Dec 17;163(7):1611-27. doi: 10.1016/j.cell.2015.11.024. Epub 2015 Dec 10.
Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, Weintraub AS, Schujiers J, Lee TI, Zhao K, Young RA. Cell. 2014 Oct 9;159(2):374-387. doi: 10.1016/j.cell.2014.09.030.
Genome-wide map of regulatory interactions in the human genome. Heidari N, Phanstiel DH, He C, Grubert F, Jahanbani F, Kasowski M, Zhang MQ, Snyder MP. Genome Res. 2014 Dec;24(12):1905-17. doi: 10.1101/gr.176586.114. Epub 2014 Sep 16.
Activation of proto-oncogenes by disruption of chromosome neighborhoods. Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, Goldmann J, Lajoie BR, Fan ZP, Sigova AA, Reddy J, Borges-Rivera D, Lee TI, Jaenisch R, Porteus MH, Dekker J, Young RA. Science. 2016 Mar 25;351(6280):1454-1458. doi: 10.1126/science.aad9024. Epub 2016 Mar 3.
A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, Sanborn AL, Machol I, Omer AD, Lander ES, Aiden EL. Cell. 2014 Dec 18;159(7):1665-80. doi: 0.1016/j.cell.2014.11.021. Epub 2014 Dec 11. Erratum in: Cell. 2015 Jul 30;162(3):687-8.
SPECIFIC, PRECISE, DURABLE, NON-TRANSGENIC,